Who is eligible for clinical trial NCT06496243?

Participants must meet the protocol's inclusion criteria for Dyslipidemias. The stated age range is 18 Years to 75 Years. Confirm all requirements with the study coordinator.

Does clinical trial NCT06496243 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-04-06

Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels (NCT06496243)

A Phase 2 Study to Evaluate the Effect of Obicetrapib Alone and in Combination With Evolocumab (Repatha®) on Lipoprotein (a) in Patients With Mild Dyslipidemia: The VINCENT Study

🟢 Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: NewAmsterdam Pharma

🩺 Plain-English Summary (8th-Grade Level)

The goal of this open label 16 week trial is to evaluate Lp(a) levels for patients with elevated Lp(a) being treated with obicetrapib and obiceptrapib/evolocumab Patients will: Have baseline Lp(a) tested at randomization Take 10mg/dL obiceptrapib daily for 8 weeks and have Lp(a) tested at Week 8 Take 10 mg/dL obicetrapib daily/evolocumab 140 every other week for 8 weeks and have Lp(a) retested at Week 16

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (3 items) and avoid the listed exclusions (3 items).

Location: UPenn — Philadelphia, Pennsylvania

Age range: 18 Years to 75 Years

🧪 Interventions in This Study

obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks (DRUG)

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Lp(a): \>=50 mg/dL (\>=125 nmol/L) for cohort 1 (FILLED) and Lp(a) \>= 20 mg/dL (\>= 50 nmol/L) to \<50 mg/dL (\< 125 nmol/L) for cohort 2
LDL-C \>70 mg/dL
TG \< 400mg/dL (\<4.52 mmol/L)

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
HbA1c\>=10 or FPG \>=270 mg/dL
CV events within 3 months of screen

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

UPenn — Philadelphia, Pennsylvania

📞 Contact the Study Coordinator

Phone: (919) 641-5724

Email: ashley.walker@newamsterdampharma.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Dyslipidemias

Evaluation of Milk Polar Lipids in Dyslipidemic Adults With Abdominal Obesity — Storrs, Connecticut
Lipid Testing After Myocardial Infarction at the Montreal Heart Institute — Montreal, Quebec
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial) — Los Angeles, California
Meta-analyses of Soy Protein and Its Food Sources for Cholesterol Reduction — Toronto, Ontario
Group Medical Visits for Patients With Dyslipidemia — Dieppe, New Brunswick

Explore by condition: All Dyslipidemias clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Contact the study coordinator using the phone/email above.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗